Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Rigel Pharmaceuticals, Inc. (RIGL) -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (150)	11/3/2003 9:07:07 AM
From: nigel bates	Read Replies (1) \| Respond to of 566

Chiron Grants Nonexclusive HCV License to Rigel Pharmaceuticals EMERYVILLE, Calif., Nov. 3 /PRNewswire-FirstCall/ -- Chiron Corporation (Nasdaq: CHIR - News) today announced that it has granted a nonexclusive license to Rigel Pharmaceuticals Inc. for the research, development and commercialization of small molecule therapeutics against certain hepatitis C virus (HCV) drug targets. The financial terms and other details of the license were not disclosed. "This agreement is another example of Chiron's commitment to making its technology widely available to companies that are working to discover therapeutics for hepatitis C," stated William G. Green, Esq., Chiron senior vice president and general counsel. "We continue to strategically leverage our HCV intellectual property and have an active program to license this technology to other companies while at the same time pursuing our own research of therapeutic agents for hepatitis C." About Hepatitis C In 1987, Chiron scientists Michael Houghton, Ph.D.; Qui-Lim Choo, Ph.D.; and George Kuo, Ph.D., cloned and first identified HCV as the cause of transfusion-related non-A, non-B hepatitis. This breakthrough marked the first time a virus was cloned before it had been grown in tissue culture or otherwise isolated. The Chiron scientists received the prestigious Lasker Award in recognition of this discovery. Since the initial work, Chiron has been granted more than 100 HCV-related patents in over 20 countries, including patents directed to hepatitis C polypeptides encoded throughout the genomes of HCV. Such polypeptides can be used in a variety of medical applications, including blood screening, clinical diagnosis, vaccines and as therapeutic targets for drug screening. A number of therapeutic companies have been granted nonexclusive licenses to Chiron's HCV technology for drug screening purposes, including Bristol-Myers Squibb, GlaxoSmithKline, Japan Tobacco Inc., Pfizer and